Pruritus Therapeutics Market Size (2024 - 2029)

Pruritus Therapeutic Market Analysis

The Pruritus Therapeutics Market is expected to register a CAGR of 3.5% during the forecast period.

The impact of COVID-19 on the studied market was adverse in the initial phases owing to the cancellations of elective procedures, including treatment of pruritus, which impacted the studied market. For instance, as per the IJCED article, COVID-19 posed unique challenges for all healthcare specialists, including dermatologists, while treating skin conditions, including urticaria, a common dermatological condition. However, the market started to gain traction as treatment facilities and research and development activities to develop innovative therapeutics for pruritus by market players resumed worldwide.

The high prevalence of dermatological diseases like atopic dermatitis, urticaria, cutaneous T-cell, psoriasis, and allergic contact dermatitis and the introduction of novel products to treat the diseases are expected to propel the market growth. In addition, the increasing prevalence of dermatological disorders and the presence of high unmet needs are actively affecting the growth of the studied market.

As per the IJCM article, 20% of the Indian population had skin diseases in 2020. Infections and eczema accounted for two-thirds of the skin diseases in the study population. Also, as per the Life (Basel) Journal, the prevalence of atopic dermatitis was 34% from included studies among Swedish children in 2021. Thus, the high burden of atopic dermatitis or eczema is projected to boost the demand for pruritus therapeutics, as pruritus is an after-effect of these skin diseases.

Additionally, advancements in technology, increasing product approvals, partnerships, and acquisitions by key players are helping in the market growth. For instance, in August 2022, Chugai Pharmaceutical Co. Ltd subsidiary Maruho Co. Ltd launched the anti-IL-31 receptor - a humanized monoclonal antibody Mitchga subcutaneous injection of 60 mg syringes used to alleviate the itching brought on by atopic dermatitis. Mitchga was approved by the Ministry of Health, Labour, and Welfare (MHLW) in March 2022 and listed on the national health insurance (NHI) reimbursement price list in May 2022. Such advancements and developments are likely to boost the demand and usage of pruritus therapeutics in the upcoming year.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the lack of understanding of disease pathophysiology and the availability of advanced alternative treatment options is likely to impede the market growth.

Pruritus Therapeutic Industry Segmentation

As per the scope of the report, pruritus is a condition of the skin accompanied by an unpleasant and irritating itching sensation over the skin that provokes scratching. Some chemical substances, like histamine, prostaglandins, proteases, substance P, and bile salts, may cause it. Sometimes accompanied by crusts, excoriations, hyperpigmentation, lichenification, pyoderma, increased skin creasing, and burnished nail. 

The pruritus therapeutics market is expected to grow at a CAGR of 3.5% over the forecast period. The pruritus therapeutics market is segmented by product type (corticosteroid, antihistamine, local anesthetic, counterirritant, immunosuppressant, calcineurin inhibitors, and other product types), disease type (atopic dermatitis/eczema, allergic contact dermatitis, urticaria, cutaneous T-cell, and other disease types) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.